Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 273.83M |
| Revenue (ttm) | 832,010 |
| Net Income (ttm) | -135.12M |
| Shares Out | 25.91M |
| EPS (ttm) | -6.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 193,217 |
| Open | 10.25 |
| Previous Close | 10.13 |
| Day's Range | 10.09 - 10.70 |
| 52-Week Range | 3.84 - 14.75 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 21.00 (+98.68%) |
| Earnings Date | May 8, 2024 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi... [Read more]
Financial Performance
In 2023, INO's revenue was $832,010, a decrease of -91.89% compared to the previous year's $10.26 million. Losses were -$135.12 million, -51.71% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for INO stock is "Buy." The 12-month stock price forecast is $21.0, which is an increase of 98.68% from the latest price.
News
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and pro...
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation g...
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PLYMOUTH MEETING, Pa. , Feb. 7, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , Feb. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
PLYMOUTH MEETING, Pa. , Jan. 23, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
Fireside Chat, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, January 24, 2024, at 12:00pm ET PLYMOUTH MEETING, Pa. , Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a...
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
- Combination therapy to be evaluated in a Phase 3 trial in patients with locoregionally advanced , high-risk , HPV16/18 - positive head and neck cancer PLYMOUTH MEETING, Pa. and REDWOOD CITY, Cal...
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration (FDA) to expedite review process Accelerating commercializa...
INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights
Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurren...
INOVIO Reports Inducement Grants Under Inducement Plan
PLYMOUTH MEETING, Pa. , Nov. 1, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
PLYMOUTH MEETING, Pa. , Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as...
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with...
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
• Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies • First Breakthrough Therapy designation for an INOVIO DNA medicine candida...
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PLYMOUTH MEETING, Pa. , Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling res...
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
PLYMOUTH MEETING, Pa. , July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA:
INOVIO to Present at the 2023 Jefferies Healthcare Conference
PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rel...
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PLYMOUTH MEETING, Pa. , May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgi...
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide cl...
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-rela...
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
PLYMOUTH MEETING, Pa. , April 28, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-a...